Patient characteristics
| All subjects | No rapamycin treatment | Rapamycin treated | |
| Sample size | 79 | 50 | 29 |
| Age (years) | 49.6 (11.1) | 50.6 (10.9) | 48.0 (11.5) |
| BMI (kg/m2) | 25.6 (6.1) | 25.6 (6.2) | 25.5 (6.1) |
| Disease duration (years) | 13.5 (11.0) | 13.9 (11.1) | 12.8 (11.0) |
| Postmenopause (%) | 33 | 22 | 11 |
| Phenotype | |||
| TSC (%) | 15 | 14 | 17 |
| Angiomyolipoma (%) | 65 | 72 | 52 |
| Lymphatic involvement (%) | 18 | 16 | 21 |
| Pneumothorax (%) | 25 | 30 | 17 |
| Serum VEGF-D (pg/ml) | 1250 (1201) | 1287 (1165) | 1182 (1284) |
| Lung function | |||
| FEV1 (% predicted) | 62 (21) | 69 (21) | 50 (17) |
| DLCO (% predicted) | 55 (16) | 60 (16) | 43 (11) |
| Pretreatment ΔFEV1 (ml/year) | −77 (168) | −54 (91) | −113 (241) |
Group means (SD) of subjects stratified by treatment with rapamycin.
BMI, Body mass index; DLCO, diffusing capacity of the lung for carbon monoxide (ml/min/kPa); ΔFEV1, annual decline in forced expiratory volume (ml/yr); TSC, tuberous sclerosis complex; VEGF-D, vascular endothelial growth factor-D.